510(k) Summary

JUN - 9 2011

Introduction

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

Submitter name, address, contact

Roche Diagnostics 9115 Hague Road, P.O. Box 50416 Indianapolis, IN 46250-0416 317-521-3577

Contact Person: Kelly French

Phone: 317-521-3208 Fax: 317-521-2324

Email: kelly.french@roche.com

Secondary Contact: Stephanie Greeman

Phone: 317-521-2458 Fax: 317-521-2324

Email: stephanie.greeman@roche.com

Date Prepared: May 11, 2011

Device Name

Proprietary name: Elecsys SHBG CalCheck 5

Common name: SHBG CalCheck 5

Classification name: Single (specified) analyte controls (assayed and

unassayed)

Predicate device

The Elecsys SHBG CalCheck 5 is substantially equivalent to other products in commercial distribution intended for similar use. We claim equivalency to the currently marketed SHBG CalCheck (K031698)

the currently marketed SHBG CalCheck (K031698).

Device Description The Elecsys SHBG CalCheck 5 is a lyophilized product consisting of SHBG in human and equine (horse) serum matrix. During manufacture, the analyte is spiked into the matrix at the desired concentration levels.

Intended use

The Elecsys SHBG CalCheck 5 is an assayed control for use in calibration verification and for use in the verification of the assay range established by the Elecsys SHBG quantitative assay reagent on the indicated Elecsys and cobas e immunoassay analyzers, for in vitro diagnostic use only.

Continued on next page

510(k) Summary, Continued

Comparison Table

The table below compares Elecsys SHBG CalCheck 5 with the predicate device, Elecsys SHBG CalCheck (K031698). The predicate shows that SHBG CalCheck 5 is substantially equivalent to SHBG CalCheck, with several key similarities, especially the analyte. The shaded fields indicate similar characteristics between the candidate device and the predicate device.

Characteristic	Elecsys SHBG	Elecsys SHBG CalCheck
Characteristic	CalCheck 5	(K031698)
	(Candidate Device)	(=======
Intended Use	The Elecsys SHBG Calcheck 5 is an assayed control for use in calibration verification and for use in the verification of the assay range established by the Elecsys SHBG quantitative assay reagent on the indicated Elecsys and cobas e immunoassay analyzers.	For use in the verification of the calibration established by the Elecsys SHBG regent on Elecsys 1010/2010/MODULAR ANALYTICS E170 immunoassay analyzers.
Analyte	SHBG	SHBG
Levels	Five	Three
Assay Measuring Range	0.800– 200 nmol/L	0.350 - 200 nmol/L
Check Target	Check 1: < 5 nmol/L	Check 1: 20 nmol/L
Values	Check 2: 20 nmol/L	Check 2: 80 nmol/L
	Check 3: 80 nmol/L	Check 3: 150 nmol/L
	Check 4: 150 nmol/L	
	Check 5: 200 nmol/L	1.1.1
Format	Lyophilized	Lyophilized
Handling	Reconstitute Check 1,	Reconstitute Check 1, Check
	Check 2, Check 3, Check	2, and Check 3 with exactly
	4, and Check 5 with	1.0 mL distilled or deionized
!	exactly 1.0 mL distilled or	water. Allow to stand closed
	deionized water. Allow to	for 15 minutes, then mix
	stand closed for 15	gently by inversion.
	minutes, then mix gently	1A 2
0. 1.00	by inversion.	TT
Stability	Unopened:	Unopened: ■ Store at 2-8°C until
	Store at 2-8°C until	******
	expiration date	expiration date
	Reconstituted:	Reconstituted:
	• 20-25°C: 4 hours	• 20-25°C: 4 hours
Matrix	Human serum/Horse	Human serum/Horse serum
	serum matrix	matrix

Continued on next page

510(k) Summary, Continued

Performance
Characteristics

The Elecsys SHBG CalCheck 5 was evaluated for value assignment and stability.

Page 3 of 3







Food and Drug Administration 10903 New Hampshire Avenue Building 66 Silver Spring, MD 20993

Roche Diagnostics c/o Ms. Kelly French Manager, Regulatory Affairs 9115 Hague Road, PO Box 50416 Indianapolis, IN 46250-0416

JUN - 9 2011

Re: k111349

Trade Name: Elecsys SHBG CalCheck 5 Regulation Number: 21 CFR §862.1660

Regulation Name: Quality control material (assayed and unassayed).

Regulatory Class: Class I, reserved

Product Codes: JJX Dated: May 12, 2011
Received: May 13, 2011

Dear Ms. French:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require-approval-of-a-premarket-approval-application-(PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of *In Vitro* Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Courtney Harper, Ph.D.

Director

Division of Chemistry and Toxicology Office of *In Vitro* Diagnostic Device

Evaluation and Safety

Center for Devices and Radiological Health

Enclosure

Indication for Use

510(k) Number (if known):

Device Name: Elecsys SHBG CalCheck 5					
Indication For Use:					
The Elecsys SHBG CalCheck 5 is an assayed control for use in calibration verification and for use in the verification of the assay range established by the Elecsys SHBG reagent on the indicated Elecsys and cobas e immunoassay analyzers.					
		·			
		·			
Prescription Use X (21 CFR Part 801 Subpart D)	And/Or	Over the Counter Use (21 CFR Part 801 Subpart C)			
(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)					
Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)					
Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety					
510(k) K111349					